# Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

> **NCT01910220** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 125 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN1033 (SAR391786)
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01910220
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-10
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2014-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910220, "Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01910220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*